Growth tracked, but catalysts deferred — FY30 ambition clear

₹162.4 Cr Q1 annualizes to ₹649.6 Cr, at lower end of ₹650-700 range

Q1 oncology at 20%, down from 26%; registrations delayed to Q4

Mexico 70 submitted/18-19 registered; expecting 6-7 in Q2; mechanism credible

Pre-clinical just completed, clinical trials starting Nov 2026, registrations push to FY29/30

Admitted margins will remain low at ₹700 Cr (49-51%), improve only at higher scale to 47%

Registrations pushed from Q3 FY27 to Q4 FY27; 20% mix in Q1 (vs prior 26%), management acknowledges delayed approvals but reaffirms ₹100 Cr FY27 target

Prior ₹1,000 Cr by FY29 aspiration → now ₹1,500 Cr by FY30 target confirmed (management said '100% right' to ₹1,400-1,500 Cr by FY30)

Prior ₹650-700 Cr → now '₹700+ Cr'; reaffirmed at upper end, no increase in quantum but narrower range signals confidence

PPT shows ₹150 Cr 'potential'; call clarified ₹150-200 Cr range (lower for conservative guidance, upside if registrations timely)

25-30% expected; registrations delayed to Q4 FY27. Got MENA/LATAM registrations instead (Mexico, Algeria, Morocco, Tunisia). Competitive edge from 60-70 dossiers and multi-plant PIC/S certification.

India immediate post-approval; ROW markets can file after 4-month PK/PD study (40 patients), by Nov-Dec 2027 10-12 countries registered. Already filed in ~10 geographies.

Q3 or Q4 FY27 (filed agreement). Waiting for software upgradations to provide data in their format.

25-30% growth expected FY28+; by 2030 ₹1,500 Cr target (doubling by FY30). EBITDA 26-27% FY27, reaching 30% by FY29 (linear 100bps/year possible).

Expecting 6-7 registrations Q2 onwards. Mexico targeting 5 more; Saudi Arabia, Colombia, Chile ramping. MENA/GCC expected to be highest % in Q4.

Manufacturing license Nov 2026; GMP June-July 2027 after 6-month stability. ROW tender sales possible immediately with license (₹70-80 Cr FY28). Full potential ₹150-200 Cr FY29 post-bioequivalence.

6-7 molecules commercialized by Q4 FY27; remaining 32 finished by Nov-Dec, filed in Q1-Q2 FY28. ₹80-100 Cr FY28 revenue; FY29 jump to ₹400-500 Cr.

R&D completed, cell line transferred to Kwality. Pre-clinical studies Dec 2026-March 2027; clinical trials start April 2027 (1-1.5 years); launch by end of CY 2028 (before patent expiry). Will be in first wave.

Target 165-170 days by FY27-end (from 208). Payment cycle from MENA/CIS/GCC improving; recently got payments. At ₹700 Cr revenue, expect ₹300 Cr debtors (~40% of revenue).

Core moat is ability to imitate reference product formulation. Ampho B liposomal = 2nd generic; Octreotide LAR = 1st generic in 70% markets; Leuprolide = 1st in 75-80%. Formulation development + batch failures + R&D persistence key.

Improved QoQ (56-57% → 53%). At ₹700 Cr revenue should be 49-51%; ideal 47% with BE products. ROW market mix (35-40% revenue) dragging margins down.

80-85% procurement from domestic API; only 15% China. No significant disruption to date.

Receivables normalizing to 165-170 days (from 208); yes, ~40% of ₹700 Cr = ₹300 Cr in receivables by FY27-end.

Took extended loan but not utilizing. Will use ₹15-20 Cr only if cash flow disrupts. Current cash sufficient: hormone Nov, oncology March; biologics clinical trials Q2-Q3. Capex ₹185-190 Cr FY27 (hormone ₹70, oncology ₹50, BE ₹25-30, WC ₹20, R&D ₹10-15). Biosimilar clinical trials need ₹150 Cr in FY28-FY29.

Hormone ₹70 Cr, Oncology ₹50 Cr, BE ₹25-30 Cr, WC ₹20 Cr, R&D ₹10-15 Cr = ₹185-190 Cr total.

Joint venture: partner invests in fill-finish plant; Kwality provides technology/clinical data (equity stake). APIs, registrations from Kwality. Parallel registration path: dossier without clinical data submitted to get stability batch approval in Algeria; clinical data submitted later. Also exploring Mexico/LATAM JVs.

Will be ₹150-200 Cr depending on registrations. Guidance conservative (lower number) to avoid queries; upside if timely registrations.

100L approved by CDSCO; 500L already installed (5× capacity). 500L approval pending, not rushing (only taking clinical batches now). Will register post-clinical batches done.

FY29 ₹1,000 Cr base (excludes biologics/hormone); FY30 with biologics ₹200-250 Cr + hormone ₹150-200 Cr + generics growth = ₹1,400-1,500 Cr possible. '100% right' it's achievable.

FY28 ₹80-100 Cr (India only); FY29 international registrations ₹200-250 Cr (may slip to FY30). Domestic + international by FY29 = ₹280-350 Cr potential if on time.

If BE finishes on time post-GMP, then 100% achievable. But uncertain; if registrations slip, only ₹60-70 Cr from ROW tenders. FY28 or FY29 timing unpredictable.

General 75-80%; Oncology 75-80%; Cepha/Beta 20-25%; Biologics not commercialized. Oncology expansion will add 45-50%; general facility extension will add 20%.

Maintaining ₹100 Cr target. Q3-Q4 expect more generic registrations than oncology. Expect ₹100-110 Cr from oncology; bigger jump from generics.

Immediate revenue. Will submit expansion to each ministry (Europe, Hungary, INVIMA Brazil, Colombia); can use same registrations without re-audit. Start commercializing right away.

Biological commercializes FY28+, hormone FY28+. Since clinical trials ongoing, included in FY30 plans, not FY29. Hormone ROW sales possible <₹80 Cr if early; not adding to FY29 guidance.

Probably will plan something. Did buyback in Q3 FY26 but no current plan.

Generics 35-40% (LATAM 30-35%, Europe 10-15%, MENA 15-20%, GCC 10-15%). Oncology 25%, Biosimilar 15-30% (if Keytruda launched), Hormone 15-20%, Beta-lactam/Cepha 10-15%. India upside once biosimilar commercialization starts.

Q1 ₹162.4 Cr annualizes to ₹649.6 Cr; management stated multiple times '100% confident' ₹700+ Cr achieved. LATAM 35-40%, generics acceleration driving.

Contingent on 6-7 registrations per quarter; hormone commercialization Nov, Erythropoietin India launch; oncology expansion

Generics core growth; biologics/hormone kept separate as 'discretionary upside' due to R&D/regulatory delays

Contingent on timely registrations (6-7/quarter), Keytruda launch by CY28, hormone bioequivalence. Management said '100% right' and '100% possible'.

Q1 OPM 25.3%; inline with full-year 26-27% target. Margins will compress at ₹700 Cr (49-51% gross) due to ROW product mix.

~100bps improvement per year as scale increases and ROW mix shifts to higher-margin regulated markets. Optimistic given working capital cycle and RM inflation.

Uncertain pricing power for biosimilars post-patent expiry; hormone margins not quantified. Management hedged: 'definitely higher but can't predict now'.

Hormone plant Nov 2026 completion, oncology expansion March 2027, BE programs ongoing. Funded from internal cash.

Will be stretched over Q3 FY28 to Q4 FY29. Deferred expense cycle; not impacting FY27-28 immediately.

Management targets 6-7 registrations Q2+, 60-70 in 3 quarters total. But Q1 oncology delayed to Q4. Each ₹1.5-2 Cr revenue per product; 6-7/qtr miss would compress ₹50-100 Cr from FY27-28 guidance.

FY26 debtor days peaked at 208 days due to geopolitical disruption. Current target 165-170 days by FY27-end = ₹300 Cr (40% of ₹700 Cr revenue) in receivables. Further disruption (Suez Canal, sanctions) could extend to 180-200 days, worsening cash conversion.

Q1 gross margin 53% down from 56-57% prior quarter. At ₹700 Cr revenue guidance, management expects 49-51% gross margins (vs legacy 60%+). Ideal 47% only at much higher scale. This ₹100-150 Cr EBITDA headwind vs prior expectations.

Oncology registrations delayed to Q4 (was Q3). Hormone plant commissioning Nov, GMP only June 2027, limiting FY27 revenue. Erythropoietin clinical trials start Nov (initially classed as 'immediate', now Nov start = 4-5 month delay from 'end of calendar 2027' claim). Keytruda biosimilar clinical completion 1-1.5 years, CY28 patent expiry leaves narrow window.

Three biosimilar molecules in clinical trials require ₹150 Cr capex spread over Q3 FY28 to Q4 FY29. If FY27-28 revenue targets missed, cash flow from operations may not cover both capex and working capital needs, forcing debt draw.